Protagonist Therapeutics: Proprietary peptide technology platform to develop oral targeted therapy-based drugs that work by blocking biological pathways currently targeted by marketed injectable antibody drugs, and injectables for rare diseases. PTG-300, injectable hepcidin mimetic in Ph 2 Beta-Thalassemia study with initial results expected 2H19. PTG-200, partnered w Janssen, oral GI-restricted IL-23R antagonist for Crohn’s disease completed Ph 1 in November 2018. PN-943, oral GI-restricted alpha4beta7 integrin-specific antagonist in UC in Ph 1, with multiple ascending dose results expected 3Q19.
Based in...
Clinical Stage
Phase l or ll
Disease Space
Anti-inflammatory, Gastrointestinal, Hematology, Rare Disease
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Platform Technology
521 Cottonwood Drive
Suite 100
Milpitas, CA 95035
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.